The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 24, 2025
Filed:
Feb. 05, 2024
Applicant:
The Procter & Gamble Company, Cincinnati, OH (US);
Inventors:
Jayanth Rajaiah, Loveland, OH (US);
Paul Albert Sagel, Maineville, OH (US);
Franco Silva Medeiros, Loveland, OH (US);
Assignee:
The Procter & Gamble Company, Cincinnati, OH (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 8/06 (2006.01); A61C 19/06 (2006.01); A61K 8/02 (2006.01); A61K 8/22 (2006.01); A61K 8/31 (2006.01); A61K 8/34 (2006.01); A61K 8/81 (2006.01); A61K 8/86 (2006.01); A61K 8/92 (2006.01); A61N 5/06 (2006.01); A61Q 11/00 (2006.01); A61Q 11/02 (2006.01);
U.S. Cl.
CPC ...
A61K 8/064 (2013.01); A61C 19/066 (2013.01); A61K 8/0216 (2013.01); A61K 8/062 (2013.01); A61K 8/22 (2013.01); A61K 8/31 (2013.01); A61K 8/345 (2013.01); A61K 8/8111 (2013.01); A61K 8/86 (2013.01); A61K 8/92 (2013.01); A61N 5/0603 (2013.01); A61N 5/062 (2013.01); A61Q 11/00 (2013.01); A61Q 11/02 (2013.01); A61K 2800/42 (2013.01); A61K 2800/81 (2013.01); A61K 2800/87 (2013.01); A61K 2800/884 (2013.01); A61K 2800/92 (2013.01); A61N 2005/0606 (2013.01); A61N 2005/0663 (2013.01);
Abstract
A kit includes a multi-phase oral composition for whitening teeth and a delivery carrier. The multi-phase oral composition for whitening teeth includes from about 0.002% to about 30%, by weight of the multi-phase oral composition, of a discontinuous aqueous phase having up to 10%, by weight of the multi-phase oral composition, of a bleaching agent and a continuous hydrophobic phase having at least about 50%, by weight of the multi-phase oral composition, of petrolatum.